Erratum: A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: Results of a consensus process by an international working group (Leukemia (2007) vol. 21 (277-280) 10.1038/sj.leu.2404473));A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: Results of a consensus process by an international working group

Leukemia

Volumn 21, Issue 2, 2007, Pages 277-280

  Barosi, G ^a   Besses, C ^b   Birgegard, G ^c   Briere, J ^d   Cervantes, F ^e   Finazzi, G ^f   Gisslinger, H ^g   Griesshammer, M ^h   Gugliotta, L ⁱ   Harrison, C ^j   Hasselbalch, H ^k   Lengfelder, E ^l   Reilly, J T ^m   Michiels, J J ⁿ   Barbui, T ^f  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d BEAUJON HOSPITAL   (France)

^e UNIVERSITY OF BARCELONA   (Spain)

^f OSPEDALI RIUNITI   (Italy)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h UNIVERSITY OF ULM   (Germany)

ⁱ S MARIA NUOVA HOSPITAL   (Italy)

^j ST THOMAS HOSPITAL   (United Kingdom)

^k UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^l UNIVERSITY OF HEIDELBERG   (Germany)

^m Academic Unit of Haematology   (United Kingdom)

ⁿ ANTWERP UNIVERSITY HOSPITAL   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA;

ARTICLE; CLINICAL PRACTICE; CONSENSUS DEVELOPMENT; DECISION SUPPORT SYSTEM; DRUG FEVER; DRUG TOLERANCE; HEMOGLOBIN DETERMINATION; HUMAN; LEG ULCER; LEUKOCYTE COUNT; PRIORITY JOURNAL; QUESTIONNAIRE; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 33846496178     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404665     Document Type: Erratum

References (21)

1. Yabro JW. Mechanism of action of hydroxyurea. Semin Oncol 1992; 19: 1-10.
2. Tefferi A, Silverstein MN, Hoagland HC. Primary thrombocythemia. Semin Oncol 1995; 22: 334-340.
3. Randi ML, Ruzzon E, Tezza F, Luzzatto G, Fabris F. Toxicity and side effects of hydroxyurea used for primary thrombocythemia. Platelets 2005; 16: 181-184.
4. Najean Y, Rain JD. Treatment of polycythemia: The use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 1997; 90: 3370-3377.
5. Barbui T, Finazzi G. When and how to treat essential thrombocythemia. N Engl J Med 2005; 353: 85-86.
6. Dingli D, Tefferi A. A critical review of anagrelide therapy in essential thrombocythemia and related disorders. Leuk Lymphoma 2005; 46: 641-650.
7. Barbui T, Barosi G, Grossi, Gugliotta L, Liberato LN, Marchetti M et al. Practice guidelines of the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2004; 89: 215-232.
8. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D et al. United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005; 353: 33-45.
9. Randi ML, Ruzzon E, Luzzatto G. Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders. Haematologica/Hematol J 2005; 90: 261-262.
10. Silver RT. Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia. Leukemia 2005; 19: 39-43.
11. Committee of medical products for human use. European Public Assessment Report (EPAR). http://www.emea.eu.int/humandocs/PDFs/EPAR/Xagrid.
12. Saaty TL, Vargas LG. Prediction, Projection and Forecasting: Applications of the Analytic Hierarchy Process in Economics, Finance, Politics, Games and Sports. Springer: New York, NY, 1990.
13. William PL, Webb C. The Delphi technique: A methodological discussion. J Adv Nurs 1994; 19: 180-186.
14. Delbecq AL, van de Ven AH, Gustafson DH. Group Techniques for Program Planning: A Guide to Nominal Group and Delphi Processes. Scott, Foresman and Co: Glenview, IL, 1975.
15. Wallace CA, Ruperto N, Giannini E. Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology International Trials Organization; Pediatric Rheumatology Collaborative Study Group. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004; 31: 2290-2294.
16. Barosi G, Bordessoule D, Briere J, Cervantes F, Demory JL, Dupriez B et al. European Myelofibrosis Network. Response criteria for myelofibrosis with myeloid metaplasia: Results of an initiative of the European Myelofibrosis Network (EUMNET). Blood 2005; 15: 2849-2853.
17. Dolan JG. Involving patients in decisions regarding preventive health interventions using the analytic hierarchy process. Health Expectations 2000; 3: 37-45.
18. Hummel JM, Snoek GJ, van Til JA, van Rossum W, Ijzerman MJ. A multicriteria decision analysis of augmentative treatment of upper limbs in persons with tetraplegia. J Rehabil Res Dev 2005; 42: 635-644.
19. Singh S, Dolan JG, Centor RM. Optimal management of adults with pharyngitis - a multi-criteria decision analysis. BMC Med Inform Decis Mak 2006; 6: 14-27.
20. Hariharan S, Dey PK, Chen DR, Moseley HS, Kumar AY. Application of analytic hierarchy process for measuring and comparing the global performance of intensive care units. J Crit Care 2005; 20: 117-124.
21. Harmanec D, Leong TY, Sundaresh S, Poh KL, Yeo TT, Ng I et al. Decision analytic approach to severe head injury management. Proc AMIA Symp 1999, 271-275.